Thus, using SOX11 as a diagnostic marker for MCL avoids misclassification of morphologically similar CD5+ marginal zone lymphomas (MZL) or CD23- chronic lymphocytic leukemia (CLL). This evidence concerns the gene FCER2 and B-cell chronic lymphocytic leukemia.